TY - JOUR
T1 - The spectrum of early rheumatoid arthritis practice across the globe
T2 - Results from a multinational cross sectional survey
AU - Nikiphorou, Elena
AU - Galloway, James
AU - Riel, Piet van
AU - Yazici, Yusuf
AU - Haugeberg, Glenn
AU - Ostor, Andrew
AU - Gogus, Feride
AU - Kauppi, Markku
AU - Sokka, Tuulikki
N1 - Publisher Copyright:
© Clinical and Experimental Rheumatology 2017.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Objective To explore patterns of real-world early RA (ERA) care across countries. Methods An online survey was disseminated to practising rheumatologists across Europe and the US, also made accessible on social media between April and May 2015. Survey questions (n=38) assessed the structure and setting of ERA clinics, times to diagnosis and treatment, patient monitoring, guideline use and data recording. Results A total of 212 rheumatologists from 39 countries (76% European) completed the survey. 62% had an ERA clinic based at a university hospital. Patient referral to rheumatology was mainly (78%) via primary care; 44% had an agreed ERA local referral pathway, 15% a national pathway. Only 16% had dedicated ERA clinics, the majority being practitioners in Northern Europe with access to a local or national referral pathway. Data for research were collected by 42%. Treatment guidelines were followed by the majority, especially rheumatologists practising in Europe. Variations existed in the use of initial DMARDs with treatment decisions reported to be influenced by international/national guidelines in 71%/61%. No significant relationship between country gross national income and the availability of ERA clinics was seen. Conclusion This study provides comparative benchmark information regarding the global provision of ERA care. Substantial variations exist in referral and early assessment pathways with guidelines having a most apparent impact in Northern Europe. Provision of an ERA service does not appear to be constrained by cost, with conceptual factors, e.g. clinician engagement, perhaps playing a role. These initial insights could potentially help harmonise ERA management across countries.
AB - Objective To explore patterns of real-world early RA (ERA) care across countries. Methods An online survey was disseminated to practising rheumatologists across Europe and the US, also made accessible on social media between April and May 2015. Survey questions (n=38) assessed the structure and setting of ERA clinics, times to diagnosis and treatment, patient monitoring, guideline use and data recording. Results A total of 212 rheumatologists from 39 countries (76% European) completed the survey. 62% had an ERA clinic based at a university hospital. Patient referral to rheumatology was mainly (78%) via primary care; 44% had an agreed ERA local referral pathway, 15% a national pathway. Only 16% had dedicated ERA clinics, the majority being practitioners in Northern Europe with access to a local or national referral pathway. Data for research were collected by 42%. Treatment guidelines were followed by the majority, especially rheumatologists practising in Europe. Variations existed in the use of initial DMARDs with treatment decisions reported to be influenced by international/national guidelines in 71%/61%. No significant relationship between country gross national income and the availability of ERA clinics was seen. Conclusion This study provides comparative benchmark information regarding the global provision of ERA care. Substantial variations exist in referral and early assessment pathways with guidelines having a most apparent impact in Northern Europe. Provision of an ERA service does not appear to be constrained by cost, with conceptual factors, e.g. clinician engagement, perhaps playing a role. These initial insights could potentially help harmonise ERA management across countries.
KW - Disease-modifying anti-rheumatic treatment
KW - Early rheumatoid arthritis
KW - Health service delivery
UR - http://www.scopus.com/inward/record.url?scp=85020257691&partnerID=8YFLogxK
M3 - Article
SN - 0392-856X
VL - 35
SP - 477
EP - 483
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - 3
ER -